TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26293575

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 μg (twice daily)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Formoterol 9 μg (twice daily)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Reliever salbutamol 90 μg
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Mean reliever use over 1 week
Number of subjects: 810
Study: 24066178

Group type: EXPERIMENTAL
Intervention: Personalised feedback about physical activity (simple, visual, or contextualised)
Number of subjects: 466
Study: 21893941

Group type: EXPERIMENTAL
Intervention: low-dose GH therapy (0.033 mg/kg/day) for 2 years
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: high-dose GH therapy (0.100 mg/kg/day) for 1 year
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: mid-dose GH therapy (0.067 mg/kg/day) for 1 year
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: GH treatment (all doses)
Number of subjects: 149
Study: 19682793

Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid blockade)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 17185207

Group type: EXPERIMENTAL
Intervention: Peer counseling + Contingency contracting (PC + CC)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Peer counseling (PC)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Contingency contracting (CC)
Number of subjects: 794
Study: 15145300

Group type: EXPERIMENTAL
Intervention: Add-on melatonin (MEL)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Add-on placebo (P)
Number of subjects: 31
Study: 11441213

Group type: EXPERIMENTAL
Intervention: Mental Adjustment to Stroke Scale (self-rated attitude scale)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Mood assessments (Hospital Anxiety and Depression Scale, General Health Questionnaire 30)
Number of subjects: 372
Study: 9836525

Group type: EXPERIMENTAL
Intervention: Nocturnal hypoglycemia (48 +/- 2 mg/dl)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nocturnal euglycemia (109 +/- 1 mg/dl)
Number of subjects: 15
Study: 8020526

Group type: EXPERIMENTAL
Intervention: iomeprol 350 mgI/ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: iopromide 370 mgI/ml
Number of subjects: 100
Study: 2246716

Group type: EXPERIMENTAL
Intervention: Educational intervention to reduce energy-dense foods and rely on child's appetite control
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 7435247

Group type: EXPERIMENTAL
Intervention: Conventional hydralazine q.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Conventional hydralazine b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slow-release hydralazine b.i.d.
Number of subjects: 20
Study: 31929980

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/day
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/bid
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control (standard dosage of esomeprazole)
Number of subjects: 1
Study: 27681944

Group type: EXPERIMENTAL
Intervention: dalotuzumab 10 mg/kg once weekly (arm A)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: dalotuzumab 7.5 mg/kg every second week (arm B)
Number of subjects: 69

Group type: COMPARATOR
Intervention: placebo (arm C)
Number of subjects: 69
Study: 24933340

Group type: EXPERIMENTAL
Intervention: Active arm of the study (screened for complications)
Number of subjects: 599
Study: 23543346

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flurbiprofen and Fentanyl
Number of subjects: 25
Study: 21816977

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT)
Number of subjects: 1533

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 1533
Study: 19508464

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 1013

Group type: COMPARATOR
Intervention: atorvastatin 10 mg/day
Number of subjects: 1013

Group type: COMPARATOR
Intervention: atorvastatin 20 mg/day
Number of subjects: 1013

Group type: COMPARATOR
Intervention: atorvastatin 40 mg/day
Number of subjects: 1013
Study: 18056233

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Cognitive remediation with adjunctive psychiatric rehabilitation
Number of subjects: 1151
Study: 15384877

Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed preterm formula
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed preterm formula
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard preterm formula
Number of subjects: 122
Study: 11846130

Group type: COMPARATOR
Intervention: Filtered products
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Non-filtered products
Number of subjects: 431
Study: 9740915

Group type: EXPERIMENTAL
Intervention: Endoscopically-guided cultures from chronic sinusitis patients
Number of subjects: 265

Group type: COMPARATOR
Intervention: Topical nasal steroids
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group of healthy volunteers
Number of subjects: 265
Study: 8049498

Group type: EXPERIMENTAL
Intervention: Sulofenur (LY186641) given orally daily x 21 schedule
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sulofenur (LY186641) given orally daily x 5 for 3 weeks schedule
Number of subjects: 32
Study: 2924255

Group type: EXPERIMENTAL
Intervention: Intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses (treatment 1)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Less intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses (treatment 2)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 434
Study: 985067

Group type: EXPERIMENTAL
Intervention: Selective myocardial hypothermic arrest (15 to 18 C) with coolant perfusion (7 to 10 C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventricular fibrillation and moderate hypothermia
Number of subjects: 0
Study: 31290761

Group type: EXPERIMENTAL
Intervention: Sexual activity and functioning in postmenopausal women
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Partner's medical condition or sexual dysfunction
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Own physical health or menopause-related symptoms
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Low libido
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Relationship problems
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Logistics and perceptions of ageing
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Positive sexual experiences
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Seeking medical help for sexual problems
Number of subjects: 4418
Study: 28715503

Group type: EXPERIMENTAL
Intervention: Aspirin continuation (100 mg/day until operative day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aspirin discontinuation (4 days before the operative day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspirin continuation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aspirin discontinuation
Number of subjects: 48
Study: 26168823

Group type: COMPARATOR
Intervention: Propofol for anesthetic maintenance (Group A)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane (0.8% end-tidal) with propofol (Group B)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 122
Study: 23883691

Group type: EXPERIMENTAL
Intervention: Isotonic sports drink (osmolality 317 mOsm/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hypotonic sports drink (osmolality 193 mOsm/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 6
Study: 21725231

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 39
Study: 19372325

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 44
Study: 16443448

Group type: EXPERIMENTAL
Intervention: Principled connections
Number of subjects: 0
Study: 15067027

Group type: EXPERIMENTAL
Intervention: S plus CT (Surgery plus Chemotherapy)
Number of subjects: 3791

Group type: EXPERIMENTAL
Intervention: S plus RT plus CT (Surgery plus Radiotherapy plus Chemotherapy)
Number of subjects: 3791
Study: 11744592

Group type: EXPERIMENTAL
Intervention: IntelliCath(TM) catheter
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: OptiQ(TM) catheter
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional bolus thermodilution
Number of subjects: 19
Study: 9304439

Group type: EXPERIMENTAL
Intervention: 0.25% WP-934 ophthalmic solution
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.5% WP-934 ophthalmic solution
Number of subjects: 29
Study: 7686715

Group type: COMPARATOR
Intervention: Intravenous piperacillin (PIPC) 2 g once after surgery, and twice on the following day (Group A)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intravenous piperacillin (PIPC) followed by oral tosufloxacin tosilate (TFLX) 300 mg twice daily from the second to the fifth day (Group B)
Number of subjects: 104
Study: 3795301

Group type: EXPERIMENTAL
Intervention: Cefoxitin (1.0 gm IV q 6 h) starting before tube thoracostomy and terminating 12 hours after removal
Number of subjects: 58

Group type: COMPARATOR
Intervention: No antibiotic therapy
Number of subjects: 58
Study: 31066988

Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 88

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 88
Study: 28605224

Group type: EXPERIMENTAL
Intervention: HEK (phase change heat emergency kit)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CON (control, without HEK)
Number of subjects: 26
Study: 26855430

Group type: EXPERIMENTAL
Intervention: Early cuff deflation and insertion of an in‐line speaking valve during mechanical ventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard cuff deflation and a speaking valve during self‐ventilation
Number of subjects: 30
Study: 25267335

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve blocks with ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided nerve blocks with saline (control)
Number of subjects: 60
Study: 22805598

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (SMS and mobile phone voucher component)
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (specifically for urban women)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (rural women)
Number of subjects: 2550
Study: 20863932

Group type: COMPARATOR
Intervention: Subcutaneous Tramadol (1.5 mg.kg⁻¹)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous Tramadol (1.5 mg.kg⁻¹)
Number of subjects: 30
Study: 18175231

Group type: EXPERIMENTAL
Intervention: Substance abuse in fathers
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Depression in mothers
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Obesity in mothers
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lifetime mood disorder in participants
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Severe depression in mothers
Number of subjects: 94
Study: 16009149

Group type: EXPERIMENTAL
Intervention: Aspiration of peritoneal fluid at laparoscopic surgery
Number of subjects: 99
Study: 12552190

Group type: EXPERIMENTAL
Intervention: Aprotinin (n = 23), bolus of 2 x 10(6) kallikrein inactivator units (KIU), followed by an infusion of 5 x 10(5) KIU/h
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Epsilon amino‐caproic acid (EACA) (n = 22), bolus of 150 mg/kg, followed by a 15 mg/kg/h infusion
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline placebo (n = 24)
Number of subjects: 69
Study: 10912891

Group type: EXPERIMENTAL
Intervention: Shoe Condition 1 (SC1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Shoe Condition 2 (SC2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Shoe Condition 3 (SC3)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mislead group (SC1 and SC3 described as baseline measures)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no investigator description)
Number of subjects: 19
Study: 8696647

Group type: EXPERIMENTAL
Intervention: Self-donated blood for pleurodesis (50 ml instillations, 120 ml for 1 patient)
Number of subjects: 14
Study: 1802958

Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine (HB Vax, MSD)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Recombinant hepatitis B vaccine (Engerix B, SK&F)
Number of subjects: 167
Study: 6478342

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mozes Detector
Number of subjects: 62
Study: 31487868

Group type: EXPERIMENTAL
Intervention: Medical condition (diagnosed with food addiction)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Self-diagnosed condition (believed herself to be a food addict)
Number of subjects: 962

Group type: COMPARATOR
Intervention: Control condition (no reference to food addiction)
Number of subjects: 962
Study: 29851819

Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-task training combined with auditory motor synchronization training (CMDT + AMST), 3 sessions per week for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cognitive-motor dual-task training (CMDT), 3 sessions per week for 6 weeks
Number of subjects: 30
Study: 26708615

Group type: EXPERIMENTAL
Intervention: Vibrating vaginal pelvic floor training balls for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises for 12 weeks
Number of subjects: 56
Study: 25261340

Group type: EXPERIMENTAL
Intervention: Analgesia-expectation condition
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control-expectation condition
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Placebo treatment (blue-colored hand disinfectant)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low-MT boys
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High-MT boys
Number of subjects: 49
Study: 22103778

Group type: COMPARATOR
Intervention: COXIB group (n = 30) received either 40 mg parecoxib iv or 120 mg etoricoxib orally 1 h before surgery.
Number of subjects: 89

Group type: COMPARATOR
Intervention: STEROID group (n = 30) received 8 mg dexamethasone iv.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Group COMBI (n = 29) received both COX-2 inhibitor and dexamethasone.
Number of subjects: 89
Study: 20854949

Group type: EXPERIMENTAL
Intervention: Smoking cessation at 6-month follow-up
Number of subjects: 2231
Study: 17634165

Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) at doses of 300 mg, 600 mg, and 1200 mg per day
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 16086879

Group type: EXPERIMENTAL
Intervention: NO regimen (LOHP plus NVB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: NP regimen (DDP plus NVB)
Number of subjects: 90
Study: 12815799

Group type: EXPERIMENTAL
Intervention: Tilt test in early stage IPD patients (n = 20)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tilt test in advanced stage IPD patients (n = 15)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tilt test in control group (n = 35)
Number of subjects: 35
Study: 9471044

Group type: EXPERIMENTAL
Intervention: Transurethral bladder neck incision
Number of subjects: 73
Study: 7635581

Group type: EXPERIMENTAL
Intervention: 40-Hz EEG measures during preinduction resting conditions
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: N1 amplitudes recorded during hypnosis
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 41
Study: 2694857

Group type: EXPERIMENTAL
Intervention: Oral Midazolam (0.3 mg/kg bw)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rectal Midazolam (0.5 mg/kg bw)
Number of subjects: 60
Study: 7373

Group type: EXPERIMENTAL
Intervention: Metoprolol 25 mg three times daily for 1 week, then 100 mg three times daily for 5 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31683110

Group type: EXPERIMENTAL
Intervention: Agricultural interventions with behavior change communication strategies (village health committees or older female leaders)
Number of subjects: 0
Study: 31568009

Group type: EXPERIMENTAL
Intervention: 20mg of methylprednisolone twice daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28338229

Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity endurance exercise training for 16 weeks
Number of subjects: 48
Study: 25187393

Group type: EXPERIMENTAL
Intervention: Multi-axis shoulder abduction splint
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (unsplinted)
Number of subjects: 24
Study: 23433098

Group type: EXPERIMENTAL
Intervention: Parent/smoker role conflict (measured by agreement with the statement about smoking interfering with parenting)
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Parent/smoker role conflict
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Planning to quit smoking in the next 30 days
Number of subjects: 1980
Study: 21474024

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver (ARM) with positive end expiratory pressure of 30 cmH₂O and inspiratory plateau pressure of 45 cmH₂O for 2 minutes after pneumoperitoneum deflation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 18637615

Group type: EXPERIMENTAL
Intervention: Remifentanil-Ketamine group (remifentanil 0.2 microg/kg/min + ketamine 1 microg/kg/min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Remifentanil-Ketamine group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Remifentanil group (remifentanil 0.2 microg/kg/min)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Remifentanil group
Number of subjects: 32
Study: 17060763

Group type: COMPARATOR
Intervention: Postoperative enteral feeding with synbiotics (group A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Preoperative plus postoperative synbiotics (group B)
Number of subjects: 101
Study: 15001641

Group type: EXPERIMENTAL
Intervention: Urocortin-1 infusion (50 micro g iv over 1 h)
Number of subjects: 8
Study: 11711841

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Travoprost 0.0015%
Number of subjects: 573

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 573
Study: 9386070

Group type: EXPERIMENTAL
Intervention: Reoperative CABG (EF <36%)
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Primary CABG (EF <36%)
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Reoperative CABG (EF <25%)
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Primary CABG (EF <25%)
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Reoperative CABG (EF <25% vs 25% to 35%)
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Reoperative CABG
Number of subjects: 1429
Study: 7523776

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg orally daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3232776

Group type: EXPERIMENTAL
Intervention: Thiopentone (5 mg/kg) followed by suxamethonium (1.5 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg/kg) followed by thiopentone (5 mg/kg)
Number of subjects: 30
Study: 28882740

Group type: EXPERIMENTAL
Intervention: Sleep-deprived state (after a night shift duty)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control state (after a night of sleep)
Number of subjects: 48
Study: 28874177

Group type: EXPERIMENTAL
Intervention: SELEVER intervention group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SELEVER with an intensive WASH component
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group without intervention
Number of subjects: 120
Study: 24308798

Group type: EXPERIMENTAL
Intervention: Weekly peer-based social skills training
Number of subjects: 207

Group type: COMPARATOR
Intervention: Universal social-emotional curriculum
Number of subjects: 207
Study: 23875866

Group type: EXPERIMENTAL
Intervention: Continuum of Care for Frail Older People
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study: 20929988

Group type: EXPERIMENTAL
Intervention: Pharmacists added to primary care teams
Number of subjects: 260
Study: 18812476

Group type: EXPERIMENTAL
Intervention: Albiglutide 32 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Albiglutide (16 or 64 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 100
Study: 17161781

Group type: EXPERIMENTAL
Intervention: Stepped waveform
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50/50% tilt biphasic
Number of subjects: 20
Study: 14760437

Group type: EXPERIMENTAL
Intervention: Physical activity and cardiorespiratory fitness assessment
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Follow-up blood pressure measurements
Number of subjects: 385
Study: 10627329

Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spastic children
Number of subjects: 40
Study: 9186882

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Strict blood pressure control
Number of subjects: 840

Group type: COMPARATOR
Intervention: Baseline factors
Number of subjects: 840
Study: 8255512

Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg o.d.)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Metoprolol (200 mg o.d.) and Chlorthalidone (25 mg o.d.)
Number of subjects: 13
Study: 3545685

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ranitidine (300 mg per day)
Number of subjects: 17
Study: 28439790

Group type: EXPERIMENTAL
Intervention: Modified NIATx Process Improvement Strategy
Number of subjects: 14